Drug intelligence / Profile preview

perindopril erbumine + indapamide

Development stage
Unknown
Lead developer
Servier
Modality
Small Molecules
Administration
Oral
01

Overview

Perindopril erbumine + indapamide is a fixed-dose combination (FDC) medication used for the management of essential hypertension. It combines perindopril erbumine, a long-acting angiotensin-converting enzyme (ACE) inhibitor, with indapamide, a thiazide-like diuretic. Perindopril acts as a prodrug for perindoprilat, which inhibits ACE, thereby reducing the production of angiotensin II, decreasing aldosterone secretion, and increasing levels of the vasodilator bradykinin. Indapamide exerts its diuretic effect by inhibiting sodium reabsorption in the distal convoluted tubule of the kidney. The combination provides a synergistic antihypertensive effect, often used when blood pressure is not adequately controlled by monotherapy. It is available in several dose strengths and is marketed globally under various brand names.

Brand names
PreteraxBi-PreteraxNoliprelSandoz Perindopril Erbumine/IndapamideCoversyl Plus
Other names
Perindopril tert-butylamine + indapamide
02

Targets

KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)ACE (Angiotensin Converting Enzyme)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on perindopril erbumine + indapamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on perindopril erbumine + indapamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call